Welcome to our dedicated page for Fennec Pharmaceuticals news (Ticker: FENC), a resource for investors and traders seeking the latest updates and insights on Fennec Pharmaceuticals stock.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutical company focused on reducing cisplatin-induced ototoxicity in cancer patients through its therapy PEDMARK®. The FENC news feed on Stock Titan aggregates company announcements, clinical updates, capital markets activity and regulatory developments that shape the outlook for this ototoxicity-focused business.
Investors and healthcare observers can review news about regulatory and commercial milestones for PEDMARK® in the United States and PEDMARQSI® in Europe and the U.K., as well as licensing developments with Norgine Pharmaceuticals Ltd. Updates on investigator-initiated and investigator-sponsored trials, including studies in Japan and at institutions such as City of Hope, provide insight into how PEDMARK® is being evaluated across different tumor types, age groups and geographies.
The Fennec news stream also covers financing transactions and balance sheet actions, such as underwritten public offerings of common shares, non-brokered offerings in Canada, and the use of proceeds to repurchase and redeem senior secured floating rate convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP. These items help investors understand how the company funds commercialization and clinical collaborations while managing its capital structure.
Additional releases may highlight participation in healthcare conferences, changes in institutional shareholdings, and other corporate communications. By following this page, readers can access an organized view of Fennec’s official disclosures, from clinical data readouts and commercialization updates to securities offerings and debt redemptions, all in one place.
Fennec Pharmaceuticals announced receiving a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for PEDMARK™. The CRL, received on August 10, 2020, cites deficiencies identified in the manufacturing facility that need resolution before approval. No clinical safety or efficacy issues were noted, and no additional clinical data is required. The company, with approximately $38.7 million in cash as of June 30, 2020, plans to hold a Type A meeting with the FDA to discuss the necessary steps for resubmission.